【DT新材料】 获 悉， 9月14日，"第二届国际绿碳科学大会（ICGC 2025）"在青岛开幕，首届" 绿碳杰出成就奖 "颁发，何鸣元、谭天伟、米夏埃 尔·格雷策尔三位科学家获得殊荣。在 绿色生物制造领域 ， 中国工程院院士、北京化工大学谭天伟教授 是中国生物化工领域的领军者，以创新驱动生 物炼制行业变革，系统推动我国绿色生物制造体系建设与发展，为全球可持续发展贡献"中国方案"。 会议期间， 《中国科学报》记者对 中国工程院院士谭天伟进行了专访。 《中国科学报》 ：作为中国生物化工领域的领军者，你对获得首届"绿碳杰出成就奖"有何感想？你认为中国发展绿色生物制造对于实现"双碳"目标的 核心价值是什么？未来十年，绿色生物制造的最关键突破点会在哪些方向？ 谭天伟 ：这份荣誉不属于我个人，属于我的团队，属于所有为中国绿色生物制造事业奋斗的同仁。这既是对我们过去工作的肯定，也是对"生物制 造"这一战略方向重要性的认可。 中国发展绿色生物制造对于实现"双碳"目标的核心价值在于提供了一条 "不减增长、只减排放"的发展新路径，是破解"发展"与"降碳"两难命题的关 键。 未来十年，绿色生物制造领域将在人工智能驱动的菌种智造、 ...

Core Viewpoint - The article emphasizes the significance of green bio-manufacturing as a sustainable development frontier, predicting that by the end of this century, bio-manufactured products could cover 70% of chemical manufacturing products, with bio-manufacturing potentially accounting for one-third of global manufacturing by 2050, creating an economic value of $30 trillion [4][5]. Group 1: Green Bio-Manufacturing Potential - The current scale of the bio-manufacturing industry is less than $8 trillion, indicating substantial growth potential in the future [4]. - The third generation of bio-manufacturing, which utilizes carbon dioxide as a raw material, is expected to significantly contribute to carbon neutrality efforts [5]. Group 2: Key Challenges and Innovations - Major scientific challenges include efficiently capturing and activating inert carbon dioxide molecules, requiring the design of new enzyme catalysts and light-enzyme coupling systems [5]. - Engineering challenges involve scaling up efficient but fragile biological systems to create stable, continuous, and low-cost reactors, transitioning from laboratory to industrial scale [5]. Group 3: Interdisciplinary Collaboration - Achieving deep integration across disciplines such as biology, chemistry, materials science, and information technology requires the establishment of project communities, shared platforms, and talent communities [6]. - Educational reforms are necessary to cultivate interdisciplinary talent capable of leading the next industrial revolution, including curriculum changes and new evaluation methods [6]. Group 4: China's Position in Global Green Technology - China is transitioning from a "follower" to a "leader" in the global green technology race, with advantages in applied research, industrialization, and market scale [7]. - The proposed international cooperation model emphasizes open collaboration in basic research, innovation alliances in key technology areas, and self-reliance in core competitive fields [7].

精构生物成立于2023年，是一家专注于合成生物技术应用的创新型企业，聚焦人类营养保健、饲料添加 等刚需领域，致力于打造国内领先、国际一流的绿色生物制造平台。 本轮融资将重点用于公司研发投入及生产基地产能建设，加速高附加值营养保健与饲料添加产品的规模 化生产，推动绿色生物制造的商业化进程。 据天眼查，精构生物实际控制人为王志敏，合计控股55.24%。他目前担任公司董事长兼总经理。 瑞财经 王敏 9月5日，据金鼎资本消息，杭州精构生物科技有限责任公司（以下简称"精构生物"）完成 数千万A轮融资，由金鼎资本领投，海邦投资、天堂硅谷、道彤投资等机构跟投。 ...

过去一周披露的投融资案例显示，科技与制造领域依旧是一级市场关注的重点，人工智能仍是资本关注的焦点，航空航天赛道受青睐。 在科技与制造领域，湖北芯擎科技有限公司宣布完成规模超10亿元人民币的B轮融资；追梦空天科技（苏州）有限公司也宣布完成两轮累计超亿元人民币的 Pre-A++轮及战略轮融资。 医疗健康领域同样表现突出，大额融资方面，应世生物科技（南京）有限公司宣布完成超3400万美元的C轮融资，由复健资本领投，比邻星创投、澄翔资 本、昆仑资本投资，老股东恩然创投继续追加投资。 21创投不完全统计，8月18日—8月24日，报告日期内国内一级市场发生融资事件34起。其中，有27笔融资披露了融资金额和币种信息，总规模约合人民币 44.86亿元。 | 创投 215 Children | | 2025年8月18日-8月24日 国内一 | | | | --- | --- | --- | --- | --- | | | 市种 | | | 案例数(起) | | | 人民币 | | | 25 | | | 美元 | | | 2 | | | | | 注:数据由21创投根据 | | 01、芯片、人工智能完成多笔融资 本周融资数量最多的 ...

Core Viewpoint - The amino acid market in China is experiencing growth driven by downstream sectors such as feed, food processing, pharmaceuticals, and health products, with a projected demand of 575.08 million tons in 2023, but expected to decline to 561.52 million tons in 2024 due to macroeconomic factors [1][19]. Overview - Amino acids are essential components of proteins and are widely used in various industries, including feed, food, and pharmaceuticals [2][6]. - The classification of amino acids includes essential, semi-essential, and non-essential types, with specific applications based on their properties [3][4]. Market Demand and Trends - The demand for amino acids is projected to decrease in 2024, with the market size expected to drop to 60.862 billion yuan, where glutamic acid accounts for 33.35%, lysine for 32.79%, threonine for 10.11%, methionine for 13.73%, and tryptophan for 2.15% [1][19]. - There is a growing consumer preference for natural and healthy products, which is expected to boost the demand for green and environmentally friendly amino acids and derivatives [1][19]. Industry Development - The amino acid industry in China has evolved from extraction methods to microbial fermentation, significantly reducing production costs and increasing efficiency [6][7]. - The industry is witnessing consolidation, with larger companies acquiring smaller ones to enhance market share and competitiveness [7][8]. Market Policies - Recent policies in China support technological innovation and industrial upgrades in the amino acid sector, promoting the use of amino acids in feed to ensure supply safety [10][12]. Industry Chain - The upstream of the amino acid industry includes suppliers of raw materials like corn, soybeans, and wheat, while the downstream encompasses applications in feed, food processing, pharmaceuticals, and health products [13][15]. - The feed sector is the largest market for amino acids, accounting for over 60% of demand, with significant growth in industrial feed production [17][19]. Competitive Landscape - The amino acid market in China is concentrated among leading companies such as Meihua Biological Technology Group, Fujian Fufeng Group, and Zhejiang New Hope Liuhe, which dominate the market [21][25]. - Meihua Biological is the largest producer of lysine, while Fufeng Group leads in MSG production, indicating a competitive environment with significant market players [21][27]. Future Trends - There is an increasing demand for high-purity amino acids in pharmaceuticals and cosmetics, supported by national policies favoring green production methods [29][30].

Core Insights - The announcement from the National Center for Food Safety Risk Assessment indicates that the application for Steviol Glycosides (enzyme conversion method) Reb M2 as a new food additive has successfully completed the public consultation phase, paving the way for its gradual entry into the domestic food and beverage market [1] - The global sugar reduction movement is reshaping the food industry, driven by WHO recommendations to limit free sugar intake to below 10% of total energy and China's "Healthy China Action (2019-2030)" initiative, which emphasizes sugar reduction as a key aspect of national health management [1] - The introduction of Reb M2 signifies a technological turning point in the sweetener industry, overcoming the taste limitations of traditional plant-extracted sweeteners and filling the market gap for "high sweetness and natural flavor balance" [1] Industry Analysis - Natural steviol glycosides primarily consist of Stevioside, RebA, and RebC, with Stevioside and RebA accounting for over 80% of the total, both of which exhibit significant aftertaste issues that limit their application in high-end food products [2] - Reb M2 offers a unique advantage, being 150-200 times sweeter than sucrose while having zero calories and high safety, with a sweetness release curve characterized by "front sweetness soft, middle sweetness full, and back sweetness short," effectively addressing the delayed sweetness issue of traditional plant-extracted steviol glycosides [2] - The vast market potential of Reb M2 is attributed to its broad applicability, allowing it to be blended with low-sweetness sweeteners like allulose and erythritol to optimize cost and taste, or with high-sweetness sweeteners like sucralose to mask metallic aftertaste and reduce usage [2] - Reb M2 has completed empirical research across over 20 food categories, covering core sectors such as dairy products, beverages, baking, and condiments, indicating its versatility and market readiness [2] - The launch of Reb M2 is set to reconstruct the sweetness logic in the food industry through technological innovation, facilitating the transition of the steviol glycoside industry from traditional extraction processes to green biomanufacturing, and opening new avenues for companies like Rhein Biotech in the health food and beverage market [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Huafeng Chemical for the first half of 2025, indicating a decline in revenue and net profit due to various external economic challenges [2][3] - The company reported a revenue of approximately 12.137 billion yuan, a year-on-year decrease of 11.70%, and a net profit of 983 million yuan, down 35.23% compared to the previous year [3] - The chemical fiber segment generated revenue of about 4.215 billion yuan, reflecting a decline of 9.43%, while the gross profit margin increased by 3.68% to 18.65% [2] Group 2 - The global economic environment is described as complex and uncertain, influenced by factors such as U.S. tariffs and geopolitical issues, which have weakened growth momentum [2] - The domestic economy remains stable, but external changes have posed significant challenges to domestic demand, impacting product prices and profits across the industry [2] - The report indicates that the industry is experiencing a cyclical downturn, leading to an oversupply situation and a decrease in product prices compared to the previous year [2]

Core Viewpoint - The company aims to become a world-class chemical new materials technology company, focusing on high-quality development in the C2 and C3 industrial chains, with continuous innovation in functional chemicals, polymer new materials, new energy materials, hydrogen energy, and comprehensive utilization of carbon dioxide [1]. Financial Performance - The company reported a revenue of 23.46 billion yuan for the current reporting period, representing a year-on-year increase of 20.93% compared to 19.40 billion yuan in the same period last year [4]. - The net profit attributable to shareholders reached 2.74 billion yuan, up 33.44% from 2.06 billion yuan in the previous year [4]. - The net profit after deducting non-recurring gains and losses was 2.90 billion yuan, reflecting a 29.61% increase from 2.23 billion yuan [4]. - The net cash flow from operating activities was 5.05 billion yuan, a significant increase of 138.88% from 2.12 billion yuan [4]. - Basic and diluted earnings per share were both 0.81 yuan, marking a 32.79% increase from 0.61 yuan [4]. - The weighted average return on equity was 8.61%, up 0.80% from 7.81% [4]. C2 Sector Development - The company has established a comprehensive development matrix for downstream chemicals of ethylene oxide, with production capacities of 1.82 million tons of ethylene glycol, 500,000 tons of polyether monomers and surfactants, 200,000 tons of ethanolamine, and 150,000 tons of carbonates [2]. - The market share of ethanolamine and polyether monomers has steadily increased, with actual production ranking first and second nationally, respectively, both exceeding 20% market share [2]. - The company’s polyethylene and polystyrene products are tailored to market demands, with polyethylene recognized as an industry benchmark for stability and low impurity content, while polystyrene has improved toughness and high-temperature resistance, entering the core supply chain of major home appliance clients [2]. C3 Sector Development - The company has built the largest domestic and second-largest global production capacity for acrylic acid and esters [3]. - The new materials and new energy integrated project at the Pinghu base, with an annual production capacity of 800,000 tons of multi-carbon alcohol, successfully commenced operations, creating a closed-loop industrial chain with acrylic acid [3]. - The company has established the Satellite Global Company to accelerate overseas market expansion, with exports of acrylic acid and esters, polyether monomers, ethanolamine, and superabsorbent resins ranking among the top in China, collaborating with over 160 countries and regions [3].

Core Points - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI with bio-manufacturing, green chemicals, new materials, future food, and future agriculture [2][3] - The conference aims to explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the technologies and products that will sustain the vitality of the bio-manufacturing sector [2][3] - Various activities will take place during the conference, including a Youth Forum on Bio-Manufacturing, a high-level roundtable discussion, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [2][3][20] Organizational Structure - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by several institutions, including Peking University Ningbo Institute of Ocean Medicine and Ningbo Meisai Bioengineering Co., Ltd. [3] - Supporting organizations include the Chinese Society of Biotechnology's Bio-based Materials Committee and various regional bio-manufacturing alliances [3] Conference Agenda - The agenda includes registration, high-level discussions, and thematic forums on topics such as green chemicals and new materials, AI-driven innovations in bio-manufacturing, and future food and agriculture [6][7][21] - Specific sessions will cover topics like enzyme molecular engineering, bio-based carboxylic acid conversion, and the design of humanized "4D" collagen proteins [11][12][17][25] Special Acknowledgments - Several companies and institutions have been acknowledged for their support, including Ningbo Meisai Bioengineering Co., Ltd., Peking University Ningbo Institute of Ocean Medicine, and various technology firms [4] Industry Insights - The conference will also feature the release of the "China Synthetic Biology Industry Distribution Map (2025 Edition)" and a list of over 500 representative bio-manufacturing enterprises in China [50][51] - The event aims to facilitate technology transfer, product scaling, and talent acquisition within the bio-manufacturing sector [2][3]

Core Viewpoint - The article highlights the recent project announcements by Heilongjiang Xinhecheng Biotech Co., Ltd., focusing on their expansion in production capacity and the upcoming SynBioCon 2025 conference, which emphasizes advancements in synthetic biology and green manufacturing [2][5]. Group 1: Project Announcements - Heilongjiang Xinhecheng Biotech Co., Ltd. has two new projects: the A9, A10, and functional fermentation products project, and the A18, A20, and isocyanic acid project [3][4]. - The A9, A10 project aims to utilize existing facilities to establish a production capacity of 6,000 tons/year for A9, 5,000 tons/year for A10, and smaller capacities for other products, totaling various outputs [3]. - The A18, A20 project plans to produce 1,000 tons/year of A18, 10,000 tons/year of isocyanic acid, and 3,000 tons/year of A20, with an estimated investment of 83.16 million yuan [4]. Group 2: Financial Performance - Xinhecheng reported impressive financial results with revenues of 21.6 billion yuan and a net profit of 5.869 billion yuan, indicating strong growth in their operations [5]. Group 3: Upcoming Conference - The SynBioCon 2025 conference will take place from August 20-22 in Ningbo, Zhejiang, focusing on AI and synthetic biology, green chemistry, new materials, future food, and agriculture [9][10]. - The conference will feature various activities, including a youth forum, high-level discussions, and a showcase of synthetic biology innovations [9][11].